Stock AVR ANTERIS TECHNOLOGIES LTD
Add to a list
To use this feature you must be a member
Log inSign up

Anteris Technologies Ltd Stock

Equities

AVR

AU0000088841

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E.
Other stock markets
 02:10:16 2024-06-04 am EDT 		5-day change 1st Jan Change
19.01 AUD -0.21% Intraday chart for Anteris Technologies Ltd +0.85% -0.73%
May. 15 Anteris Technologies Completes Valve-in-Valve-in-Valve Procedure with DurAVR MT
Apr. 18 Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31 MT

Financials

Sales 2024 * 6M 3.99M Sales 2025 * 6M 3.99M Capitalization 365M 243M
Net income 2024 * -79M -52.52M Net income 2025 * -85M -56.51M EV / Sales 2024 * 56.7 x
Net cash position 2024 * 25M 16.62M Net cash position 2025 * 25M 16.62M EV / Sales 2025 * 56.7 x
P/E ratio 2024 *
-5.11 x
P/E ratio 2025 *
-5.43 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.81%
More Fundamentals * Assessed data

Chart Anteris Technologies Ltd

Dynamic Chart

Latest news about Anteris Technologies Ltd

Anteris Technologies Completes Valve-in-Valve-in-Valve Procedure with DurAVR MT
Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31 MT
Anteris Technologies Raises AU$23 Million for DurAVR Study MT
Anteris Declares Upbeat Results from Human Trials of Heart Valve MT
Anteris Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Anteris Technologies Completes Enrollment for Heart Valve Device Study MT
Anteris Technologies Secures AU$1 Million Tax Rebate for 2022 MT
Anteris Technologies Ltd(ASX:AVR) dropped from S&P Global BMI Index CI
Anteris Technologies Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case CI
Montefiore Enrolls Patients for US Early Feasibility Study for Anteris Technologies' DurAVR THV MT
Anteris Technologies Announces First Successful Implantation of Duravr? Thv in A Valve-In-Valve Procedure CI
Anteris Technologies Implants DurAVR THV in Valve-in-Valve Procedure; Shares Jump 3% MT
Anteris Technologies Validates Efficacy of Aortic Valve Device MT
Anteris Technologies Secures US Patent for Transcatheter Heart Valve; Shares Rise 4% MT
More news

Press releases Anteris Technologies Ltd

Anteris Technologies achieves breakthrough in triple valve replacement using DurAVRâ„¢ AQ
Anteris talks market superiority of its biomimetic TAVR valve AQ
Anteris Announces Participation at the Cantor Healthcare Conference on Sept 26th 2023 BU
Anteris Technologies Ltd - DurAVR Demonstrates Exceptional Results in Second Valve-in-Valve Case AQ
DurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve Case BU
More press releases

Quotes and Performance

1 day-0.21%
1 week+0.85%
Current month+0.05%
1 month-10.71%
3 months+10.20%
6 months-5.42%
Current year-0.73%
More quotes

Highs and lows

1 week
18.25
Extreme 18.25
19.45
1 month
18.25
Extreme 18.25
21.50
Current year
15.58
Extreme 15.58
23.93
1 year
15.58
Extreme 15.58
23.93
3 years
6.80
Extreme 6.8
30.89
5 years
3.01
Extreme 3.01
30.89
10 years
2.90
Extreme 2.9
170.00
More quotes

Managers and Directors - Anteris Technologies Ltd

Managers TitleAgeSince
Wayne Paterson CEO
 Chief Executive Officer 56 14-10-09
Matthew McDonnell DFI
 Director of Finance/CFO - 18-11-22
Chris Meduri CTO
 Chief Tech/Sci/R&D Officer - 21-09-05
Members of the board TitleAgeSince
John Seaberg CHM
 Chairman 72 14-10-09
Stephen Denaro BRD
 Director/Board Member - 18-10-30
Wayne Paterson CEO
 Chief Executive Officer 56 14-10-09
More insiders

Quotes

Date Price Change Volume
24-06-04 19.01 -0.21% 2 091
24-06-03 19.05 +0.26% 4,185
24-05-31 19 +1.33% 30,419
24-05-30 18.75 -1.21% 9,566
24-05-29 18.98 -1.15% 10,801

Delayed Quote Australian S.E., June 04, 2024 at 02:10 am EDT

More quotes

Company Profile

Anteris Technologies Ltd is an Australia-based structural heart company. The Company is engaged in designing, developing, and commercializing medical devices. The Company’s lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR THV is made using ADAPT tissue, its patented anti-calcification tissue technology. DurAVR THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. It is designed to mimic the performance of a pre-disease human aortic valve. Its balloon expandable ComASUR Delivery System provides controlled deployment and accurate placement of the DurAVR THV valve, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-08-22 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Anteris Technologies Ltd

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
19.01 AUD
Average target price
30 AUD
Spread / Average Target
+57.81%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ANTERIS TECHNOLOGIES LTD Stock Anteris Technologies Ltd
-0.73% 245M
ABBOTT LABORATORIES Stock Abbott Laboratories
-6.28% 179B
MEDTRONIC PLC Stock Medtronic plc
+0.66% 108B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-1.96% 69.03B
DEXCOM, INC. Stock DexCom, Inc.
-6.40% 45.83B
CENCORA, INC. Stock Cencora, Inc.
+12.28% 45.39B
HOYA CORPORATION Stock Hoya Corporation
+8.60% 43.17B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.66% 29.89B
TERUMO CORPORATION Stock Terumo Corporation
+13.65% 25.49B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-8.66% 23.95B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. AVR Stock